A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease.

MLA

Horne, G. A., et al. “A Randomised Phase II Trial of Hydroxychloroquine and Imatinib versus Imatinib Alone for Patients with Chronic Myeloid Leukaemia in Major Cytogenetic Response with Residual Disease.” Leukemia, vol. 34, no. 7, July 2020, pp. 1775–86. EBSCOhost, https://doi.org/10.1038/s41375-019-0700-9.

APA

Horne, G. A., Stobo, J., Kelly, C., Mukhopadhyay, A., Latif, A. L., Dixon-Hughes, J., McMahon, L., Cony-Makhoul, P., Byrne, J., Smith, G., Koschmieder, S., BrÜmmendorf, T. H., Schafhausen, P., Gallipoli, P., Thomson, F., Cong, W., Clark, R. E., Milojkovic, D., Helgason, G. V., … Copland, M. (2020). A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease. Leukemia, 34(7), 1775–1786. https://doi.org/10.1038/s41375-019-0700-9

Chicago

Horne, G A, J Stobo, C Kelly, A Mukhopadhyay, A L Latif, J Dixon-Hughes, L McMahon, et al. 2020. “A Randomised Phase II Trial of Hydroxychloroquine and Imatinib versus Imatinib Alone for Patients with Chronic Myeloid Leukaemia in Major Cytogenetic Response with Residual Disease.” Leukemia 34 (7): 1775–86. doi:10.1038/s41375-019-0700-9.